Nanomedicines Against Mitochondrial Dysfunction‐Induced Metabolic Diseases
Advanced Science · 2025-12 · 12 (48)
DOI: 10.1002/advs.202514522 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 21.11.2025. Verfasst von Ke Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Liver Transplant Center, Organ Transplant Center, Department of General Surgery, Department of Radiology, Huaxi MR Research Center (HMRRC), Instituti…. Hauptthemen laut MEDLINE: Nanomedicine, Metabolic Diseases, Mitochondria, Mitochondrial Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 305 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, the Key R&D Projects of Sichuan Province.
Abstract (Originalsprache)
Mitochondrial dysfunction is a common pathology for metabolic diseases such as obesity, diabetes, non‐alcoholic fatty liver disease, atherosclerosis, Alzheimer's disease (AD), and Parkinson's disease (PD). Nanomedicines provide a revolutionary strategy for mitochondrial function repair. They can realize targeted delivery, responsive release, and integration of multimodal therapies through nanotechnology and engineering and overcome limitations of traditional therapeutic methods, such as insufficient targeting, low bioavailability, and toxic side effects. In this article, the pathological characteristics of mitochondria are first introduced, and the relationship between mitochondrial dysfunction and metabolic diseases are illustrated. Structural features and design strategies of nanomedicines targeting mitochondrial dysfunction are summarized, with particular elaboration on targeting strategies and response mechanisms for diseased organs and subcellular organelles such as the liver, adipose tissue, atherosclerotic plaques, the brain, and mitochondria. The application and clinical translation of nanomedicines in obesity, atherosclerosis, diabetes, non‐alcoholic fatty liver disease (NAFLD), and brain metabolic disorders are detailed. This article is concluded with a summary and outlook of the current research status, challenges, and future development directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver Transplant Center, Organ Transplant Center, Department of General Surgery, Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Frontiers Science Center for Dise…
- Laboratory of Liver Transplantation, Institute of Organ Transplantation, Key Laboratory of Transplant Engineering and Immunology, NHC, West China Hospital of Sichuan University, Chengdu, 610041, China.
- Psychoradiology Key Laboratory of Sichuan Province, and Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu, 610041, China.
ORCID-Profile: Kui Luo
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- the Key R&D Projects of Sichuan Province
- 1·3·5 project for disciplines of excellence, West China Hospital, Sichuan University
Zitieren
APA
Xu, K., Wang, L., Lv, T., Jin, C., Wu, Q., Zhou, Y., Xu, G., Duan, Z., Luo, K., & Yang, J. (2025). Nanomedicines Against Mitochondrial Dysfunction‐Induced Metabolic Diseases. Advanced Science, 12(48). https://doi.org/10.1002/advs.202514522
Vancouver
Xu K, Wang L, Lv T, Jin C, Wu Q, Zhou Y, et al. Nanomedicines Against Mitochondrial Dysfunction‐Induced Metabolic Diseases. Advanced Science. 2025;12(48). doi:10.1002/advs.202514522
BibTeX
@article{Xu2025,
author = {Xu, Ke and Wang, Leyi and Lv, Tao and Jin, Chen and Wu, Qiong and Zhou, Yongjie and Xu, Gang and Duan, Zhenyu and Luo, Kui and Yang, Jiayin},
title = {Nanomedicines Against Mitochondrial Dysfunction‐Induced Metabolic Diseases},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {48},
doi = {10.1002/advs.202514522}
}
EUVIMED